Epiontis is a private company, its shareholders are its management team as well as Epigenomics AG and Bridges Consulting Group AG.
In addition to equity financing, Epiontis receives funding from several government technology grant programs, including Innovationsfonds (co-funded by the European fund for regional development) and ProFIT of the Investitionsbank Berlin, Germany, as well as “Förderschwerpunkt Tissue Engineering“ (Federal Ministry of Education and Research, Germany).